Weight Loss Drugs May Halt Knee Replacements

Recent studies indicate that weight loss medications, including widely recognized drugs like Ozempic and Wegovy, could substantially lessen the requirement for knee replacement surgery. This discovery offers a hopeful outlook for managing osteoarthritis, a common condition leading to over 110,000 total knee replacements annually in the UK alone.

The research, led by experts from the University of Maryland School of Medicine, focused on GLP-1 receptor agonists (GLP-1s), a class of drugs also including Mounjaro. While these medications are commonly prescribed for type 2 diabetes and obesity, their potential to reduce the need for knee replacement surgery had not been previously explored.

Analysis of a global patient database revealed a significantly lower incidence of total knee replacements among individuals taking GLP-1s. This protective effect was more pronounced with longer treatment durations and with newer drug versions like semaglutide and tirzepatide. Researchers estimated that in the US, three years of treatment with newer GLP-1s could lead to approximately 14,400 fewer knee replacements each year.

Experts suggest these findings point towards disease-modifying capabilities that extend beyond mere weight reduction. While further trials are necessary to confirm causality, the current evidence suggests GLP-1 RAs could be a valuable complementary strategy for managing knee osteoarthritis in eligible patients with concurrent obesity or metabolic disease.

Arthritis UK has described the study as encouraging, noting that maintaining a healthy weight is crucial for managing osteoarthritis. The research highlights the growing role of weight loss medications in improving musculoskeletal health, potentially offering a new path to avoid or delay invasive joint replacement procedures.